|23.79||+0.3600||+1.54%||Vol 1.42M||1Y Perf -26.80%|
|Dec 6th, 2023 16:00 DELAYED|
|- -||-0.28 -1.18%|
|Target Price||67.09||Analyst Rating||Moderate Buy 1.64|
|Potential %||182.01||Finscreener Ranking||★★ 46.29|
|Insiders Trans % 3/6/12 mo.||-/-100/-94||Value Ranking||★★ 45.62|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||★★★ 49.70|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||14.31||Earnings Rating||Strong Buy|
|Market Cap||2.56B||Earnings Date||27th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.70|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||3.05M|
|Avg. Monthly Volume||1.42M|
|Avg. Quarterly Volume||1.11M|
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) stock closed at 23.79 per share at the end of the most recent trading day (a 1.54% change compared to the prior day closing price) with a volume of 1.42M shares and market capitalization of 2.56B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 232 people. Arrowhead Pharmaceuticals Inc. CEO is Christopher Anzalone.
The one-year performance of Arrowhead Pharmaceuticals Inc. stock is -26.8%, while year-to-date (YTD) performance is -41.35%. ARWR stock has a five-year performance of 81.19%. Its 52-week range is between 20.67 and 42.48, which gives ARWR stock a 52-week price range ratio of 14.31%
Arrowhead Pharmaceuticals Inc. currently has a PE ratio of -22.30, a price-to-book (PB) ratio of 10.68, a price-to-sale (PS) ratio of 15.97, a price to cashflow ratio of 21.20, a PEG ratio of -, a ROA of -27.22%, a ROC of -30.91% and a ROE of -47.27%. The company’s profit margin is -55.69%, its EBITDA margin is -59.70%, and its revenue ttm is $215.79 Million , which makes it $1.90 revenue per share.
Of the last four earnings reports from Arrowhead Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.70 for the next earnings report. Arrowhead Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Arrowhead Pharmaceuticals Inc. is Moderate Buy (1.64), with a target price of $67.09, which is +182.01% compared to the current price. The earnings rating for Arrowhead Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Arrowhead Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Arrowhead Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.76, ATR14 : 1.67, CCI20 : -118.37, Chaikin Money Flow : 0.01, MACD : -0.61, Money Flow Index : 31.34, ROC : -15.22, RSI : 42.52, STOCH (14,3) : 34.55, STOCH RSI : 0.40, UO : 40.69, Williams %R : -65.45), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Arrowhead Pharmaceuticals Inc. in the last 12-months were: Christopher Anzalone (Option Excercise at a value of $485 242), Christopher Anzalone (Sold 187 021 shares of value $6 339 118 ), Douglas B. Given (Sold 8 250 shares of value $322 935 ), Hamilton James (Sold 23 841 shares of value $901 048 ), James Hamilton (Sold 20 076 shares of value $769 740 ), Kenneth Myszkowski (Sold 15 000 shares of value $543 000 ), Martin Javier San (Sold 19 700 shares of value $567 315 ), O'Brien Patrick (Sold 25 000 shares of value $951 227 ), Oliver Tracie (Sold 8 925 shares of value $315 142 ), Olukotun Adeoye (Sold 11 350 shares of value $370 578 ), Patrick O'Brien (Sold 0 shares of value $-393 600 ), Patrick O'Brien (Sold 35 000 shares of value $1 341 604 ), Vakiener Victoria (Sold 1 550 shares of value $40 812 ), Waddill William (Sold 3 200 shares of value $96 000 ), William D. Waddill (Sold 3 200 shares of value $96 000 )
Tue, 28 Nov 2023 23:55 GMT Hold Rating on Arrowhead Pharmaceuticals Awaiting ARO-DM1 Clinical Trial Results- TipRanks. All rights reserved.
Tue, 08 Aug 2023 12:55 GMT Arrowhead Pharmaceuticals (ARWR) Receives a Buy from Piper Sandler- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.